e.okafor
TL2 Moderator · Essen
Contributes reviews on supplier material. Based in Essen.
Joined 28 March 2025 · last posted 4d
71Posts here
1Topics
0Solutions
1kLikes received
1.5kLikes given
24Badges
214Days visited
4.6kPosts read
Recent activity
Full stream-
Documenting a supplier's response to a discrepancy Replied, post #47 · Sourcing › Vendor reports · 24 Jul 2026 · 16 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #115 · Evidence › Journal club · 18 Jul 2026 · 32 likes TRIUMPH (ongoing): Retatrutide phase 3. No results yet. Nothing should be attributed to it because it has not finished. When it does, this discussion will return to it.
-
Revisiting: The best-written scientific paper you have read Replied, post #85 · Lounge › Off topic · 11 Jul 2026 · 22 likes post #84 answers the question as asked. The question underneath it is different. Community norms: if you want to discuss how the community should work (not moderation…
-
Programming during a large energy deficit Replied, post #37 · Nutrition & Training › Resistance training · 11 Jul 2026 · 6 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Osteoarthritis and mechanical versus metabolic improvement — one year on Replied, post #24 · Clinical › Comorbidities · 11 Jul 2026 · 0 likes Interactions between comorbidities: diabetes and kidney disease together change the risk calculation for hypoglycemia and for medication clearance. They are not…
-
What to bring: records that a clinician can actually use — a second dataset Replied, post #8 · Clinical › Prescriber conversations · 5 Jul 2026 · 0 likes Understanding stopping rules: what would prompt stopping the compound? Adverse effect, lack of benefit after a defined time, or other reasons? Knowing in advance is…
-
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #77 · Evidence › Journal club · 3 Jul 2026 · 3 likes This follows post #74 rather than contradicting it. SURMOUNT-OSA (N Engl J Med 2024): Tirzepatide in obstructive sleep apnoea, using an objective physiological…
-
Revisiting: The best-written scientific paper you have read Replied, post #66 · Lounge › Off topic · 2 Jul 2026 · 0 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Coming back to: Where the four-week escalation interval comes from, and what it is not Replied, post #9 · Practice › Dosing & titration · 2 Jul 2026 · 1 like How the published trials escalated: they used specific step sizes and intervals. The STEP programme used a particular cadence; the SURPASS and SURMOUNT programmes used…
-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #45 · Access › International · 29 Jun 2026 · 0 likes I read post #43 twice before replying, because I had assumed the opposite. Country-by-country legality: compound approval and legal status differ substantially by…
-
Reflectance and photometric devices: precision in practice — a second dataset Replied, post #54 · Analytics › Home & field testing · 20 Jun 2026 · 8 likes Worth separating two things that post #50 runs together. What you can use home tests for: confirmation that a solution contains peptide (as opposed to being saline…
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full Replied, post #91 · Practice › Reconstitution · 20 Jun 2026 · 11 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.